Literature DB >> 8301566

Relaxant responses of rabbit aorta: influence of cytochrome P450 inhibitors.

A O Oyekan1, J C McGiff, P Rosencrantz-Weiss, J Quilley.   

Abstract

Based on the use of inhibitors, cytochrome P450 has been implicated in endothelium-dependent relaxant responses via metabolism of arachidonic acid (AA). However, the contribution of cytochrome P450 and its AA metabolites to the regulation of vascular tone has not been established due, in part, to questions of specificity of cytochrome P450 inhibitors which have not been extensively characterized in terms of their vascular effects. Consequently, we addressed the effects of several inhibitors on vasorelaxant responses of phenylephrine-contracted, rabbit, aortic rings to agents that utilize different transduction mechanisms to determine any actions unrelated to inhibition of cytochrome P450 and/or AA metabolism. Octadecynoic acid (2.5 and 5 microM), a mechanism-based inhibitor of cytochrome P450 metabolism of fatty acids, and eicosatetrayenoic acid (10 and 20 microM), an inhibitor of AA metabolism, were without effect on vasorelaxant responses to acetylcholine, sodium nitroprusside, isoproterenol and diazoxide. 7-Ethoxyresorufin (2-10 microM), a substrate for cytochrome P450, and clotrimazole (2.5-10 microM) which binds to the heme moiety of the enzyme, concentration-dependently reduced responses to acetylcholine but not the other agonists indicating an effect on nitric oxide synthesis although neither affected the conversion of L-arginine to L-citrulline by endothelial cells. SKF 525A (50-200 microM), the prototypical inhibitor of cytochrome P450, which is metabolized to an inhibitory intermediate, also reduced responses to acetylcholine and, in addition, impaired the vasorelaxant activities of isoproterenol and diazoxide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301566

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Apamin-sensitive, non-nitric oxide (NO) endothelium-dependent relaxations to bradykinin in the bovine isolated coronary artery: no role for cytochrome P450 and K+.

Authors:  G R Drummond; S Selemidis; T M Cocks
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

2.  Stable EET urea agonist and soluble epoxide hydrolase inhibitor regulate rat pulmonary arteries through TRPCs.

Authors:  Yun Liu; Ruifang Wang; Jing Li; Jingjing Rao; Weiyang Li; John R Falck; Vijay L Manthati; Meetha Medhora; Elizabeth R Jacobs; Daling Zhu
Journal:  Hypertens Res       Date:  2011-02-10       Impact factor: 3.872

3.  The mechanistic target of rapamycin (mTOR) pathway and S6 Kinase mediate diazoxide preconditioning in primary rat cortical neurons.

Authors:  Somhrita Dutta; Ibolya Rutkai; Prasad V G Katakam; David W Busija
Journal:  J Neurochem       Date:  2015-07-01       Impact factor: 5.372

4.  Inhibitors of the cytochrome P450-mono-oxygenase and endothelium-dependent hyperpolarizations in the guinea-pig isolated carotid artery.

Authors:  C Corriu; M Félétou; E Canet; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

5.  Cytochrome P450-dependent effects of bradykinin in the rat heart.

Authors:  D Fulton; K Mahboubi; J C McGiff; J Quilley
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

6.  Contribution of calcium-activated potassium channels to the vasodilator effect of bradykinin in the isolated, perfused kidney of the rat.

Authors:  M Rapacon; P Mieyal; J C McGiff; D Fulton; J Quilley
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

7.  Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet.

Authors:  K Makita; K Takahashi; A Karara; H R Jacobson; J R Falck; J H Capdevila
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

8.  Inhibition of NO-medicate responses by 7-ethoxyresorufin, a substrate and competitive inhibitor of cytochrome P450.

Authors:  C G Li; M J Rand
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.